Labgenomics Co Documents
Documents
0
Ticker
084650.KQ
ISIN
KR7084650001
Labgenomics Co SEC Filings
Type | Report | Date |
|---|---|---|
| No documents available | ||
Labgenomics Co Documents 2026
This page contains all official documents and SEC filings for Labgenomics Co stock (084650.KQ, ISIN: KR7084650001). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 0 documents are available. Data is updated regularly to provide investors with a complete overview of Labgenomics Co's regulatory filings.
Labgenomics Co Stock analysis
Labgenomics Co LabGenomics Co., Ltd. generates revenue through the provision of in vitro diagnostic (IVD) products and services. The company offers general diagnostic check services, molecular diagnostic check services, and research and development services, alongside IVD products such as DNA chips and PCR kits. Its diagnostic services include examinations for breast cancer and colorectal cancer, while its biosensor solutions target point of care testing (POCT). Additionally, LabGenomics sells healthy food as part of its product portfolio. The primary buyers of LabGenomics' services are healthcare institutions requiring diagnostic support, including hospitals and clinics. The company's molecular diagnostic services and cancer examinations are particularly sought after by medical facilities focused on specialized testing. Healthcare providers also purchase its biosensor solutions for immediate testing at the point of care. LabGenomics' product segments include IVD services, IVD products like DNA chips and PCR kits, cancer examination services, and healthy food. The company's molecular diagnostic services and cancer testing are key revenue drivers, while its biosensor for POCT and healthy food offerings serve complementary market segments.